DOCSLIB.ORG

Downloaded From

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Downloaded From A Thesis Submitted for the Degree of PhD at the University of Warwick Permanent WRAP URL: http://wrap.warwick.ac.uk/149337 Copyright and reuse: This thesis is made available online and is protected by original copyright. Please scroll down to view the document itself. Please refer to the repository record for this item for information to help you to cite it. Our policy information is available from the repository home page. For more information, please contact the WRAP Team at: [email protected] warwick.ac.uk/lib-publications A Randomized Trial of Neprilysin Inhibition with Sacubitril/valsartan vs Irbesartan in Chronic Kidney Disease by Dr Parminder Kaur Judge Thesis submitted in fulfilment of the requirements for the degree of Doctor of Philosophy (PhD) in Medicine University of Warwick & Medical Research Council Population Health Research Unit, Nuffield Department of Population Health, University of Oxford Submitted June 2020 1 Contents Section Page List of Tables 7 List of Figures 9 Acknowledgements 10 Declarations 12 Inclusion of Published Work 13 Abstract 14 Chapters 1 List of abbreviations 15 2 Introduction 19 3 Natriuretic peptide system and neprilysin 35 2 4 Angiotensin receptor-neprilysin inhibitor (ARNI) 46 Effects on renal function 50 Effects on albuminuria 53 5 Methods 65 Trial organisation 70 Staff training 70 Data management 70 Trial treatments 70 Consent 72 Biological samples 73 Randomized treatment and blinding 76 Blood and urine samples 76 3 Adverse events and compliance with trial treatment 77 Physical measurements 78 Blood and urine samples 78 Central laboratory methods 79 Issuing trial treatment 79 Final follow-up and mGFR 79 Analysis of Covariance (ANCOVA) 82 Repeated measures analyses of biomarkers 83 Imputation of missing data 83 Imputation of the primary outcome data 84 6 Trial Management 87 Trial protocol 88 Standard Operating Procedures and internal operating procedures 89 Participant-facing documents 90 Recruitment 97 Key data 98 Compliance 98 Data errors 99 4 CCO monitoring 100 Independent DMC monitoring 102 7 Results 103 Renal safety data 135 Liver safety data 135 8 Discussion 137 5 Effect of renin-angiotensin system inhibition on glomerular haemodynamics in heart failure 147 Effect of neprilysin inhibition on glomerular haemodynamics in heart failure 147 Effect of angiotensin receptor-neprilysin inhibition on glomerular haemodynamics in heart failure 148 Effects of renin angiotensin system inhibition on glomerular haemodynamics in CKD 148 Possible effect of neprilysin inhibition on glomerular haemodynamics in CKD149 Hyperkalaemia 159 Acute kidney injury 160 9 References 165 6 List of Tables Table 1: Prevalence estimates of chronic kidney disease in the United States by stage 19 Table 2: Examples of vasopeptidase inhibitors produced and studied in humans 41 Table 3: Angioedema rates in PARADIGM-HF patients treated with sacubitril/valsartan and enalapril 58 Table 4: Renal safety data from PARAMOUNT with sacubitril/valsartan and valsartan-alone 59 Table 5: Renal adverse events following treatment with sacubitril/valsartan in patients with heart failure 59 Table 6: UK HARP-III trial aims 66 Table 7: UK HARP-III trial inclusion and exclusion criteria 68 Table 8: Planned central laboratory blood and urine analyses 77 Table 9: Continuous and categorical data in UK HARP-III 82 Table 10: Reasons for ineligibility for UK HARP-III during the screening visit 106 Table 11: Reasons for withdrawal from pre-randomization run-in 107 Table 12: Any adverse event during pre-randomization run-in 108 Table 13: Reasons for ineligibility at randomization 109 Table 14A: Baseline characteristic of UK HARP-III participants randomized 110 Table 14B: Baseline characteristic of UK HARP-III participants randomized 111 Table 15: Compliance with trial follow-up visits following randomization in UK HARP-III 113 Table 16: Compliance with randomized treatment in UK HARP-III 115 Table 17: Reasons for stopping full dose randomized study treatment 116 Table 18: Reasons for completely stopping randomized study treatment 118 Table 19: Primary outcome: Effect of sacubitril/valsartan on rate of change in measured glomerular filtration rate at 12 months 119 Table 20: Pre-specified sensitivity analysis of the effect of randomization to sacubitril/valsartan on measured glomerular filtration rate as 12 months, excluding participants with missing measured glomerular filtration rate values at 12 months 120 Table 21: Effect of randomization to sacubitril/valsartan on urinary albumin:creatinine ratio at 3, 6 and 12 months 123 Table 22: Post-hoc exploratory analysis analysing the effect of allocation to sacubitril/valsartan on study average urinary albumin:creatinine ratio in a range of subgroups 124 Table 23: Effect of randomization to sacubitril/valsartan on rate of change in estimated glomerular filtration rate slopes 125 Table 24: Effect of randomization to sacubitril/valsartan on systolic and diastolic blood pressure 126 Table 25: Effect of randomization to sacubitril/valsartan on cardiac biomarkers 127 Table 26: Post-hoc assessment of the effect of sacubitril/valsartan on NT-proBNP 128 Table 27: Post-hoc assessment of the effect of sacubitril/valsartan on troponin I 129 7 Table 28: Associations between baseline characteristics and sacubitril/valsartan metabolite values at the 3 month visit 130 Table 29A: Effect of randomization to sacubitril/valsartan on serious adverse events 131 Table 29B: Effect of randomization to sacubitril/valsartan on serious adverse events 132 Table 30A: Effect of sacubitril/valsartan on non-serious adverse reactions 133 Table 30B: Effect of sacubitril/valsartan on non-serious adverse reactions 134 Table 31: Effect of sacubitril/valsartan on renal safety outcomes 135 Table 32: Effect of sacubitril/valsartan on liver safety outcomes 136 8 List of Figures Figure 1: Renin-angiotensin system 21 Figure 2: Renin-angiotensin system and sites of therapeutic blockade 23 Figure 3: Mechanism of action of natriuretic peptides and neprilysin 36 Figure 4: Production and metabolism of bradykinin 44 Figure 5: Mechanism of action of angiotensin receptor-neprilysin inhibitors 45 Figure 6: Difference in mean sitting systolic and diastolic blood pressure (BP) at 8 weeks with maximum sacubitril/valsartan (S/V; n=170) dose compared with full dose valsartan (n=163) 48 Figure 7: UK HARP-III trial design overview 69 Figure 8: Numbers of participants screened using the pre-screening and traditional methods of recruitment 104 Figure 9: Flow of participant through the UK HARP-III trial 105 Figure 10: Five-year risk of progression to End-stage kidney disease among UK HARP-III participants 113 Figure 11: Effect of sacubitril/valsartan on measured glomerular filtration rate at 12 months in a range of pre-specified sub-groups 121 Figure 12: Effect of randomization to sacubitril/valsartan on estimated glomerular filtration rate 122 9 Acknowledgements I would first like to thank the participants of the UK Heart and Renal Protection (HARP)- III trial without whom it would not have been possible to undertake this research. I am incredibly thankful to my supervisor, Professor Richard Haynes (Medical Research Council Population Health Research Unit [MRC PHRU], University of Oxford and Honorary Consultant Nephrologist, Oxford University Hospitals NHS Foundation Trust), for all his guidance, patience, kindness and friendship. He provided me with the opportunity and encouragement to undertake research in clinical trials at the MRC PHRU and through this mentorship, initiated my desire and motivation to pursue a career in clinical research and clinical trials. The opportunities and ongoing support he has always provided me over many years, has been instrumental to me gaining my current role as Senior Clinical Research Fellow within the Renal Studies Group, University of Oxford, and so I will be forever indebted to him. I am hugely grateful to Professor Colin Baigent (Professor of Epidemiology and Director of MRC PHRU, University of Oxford) for all his encouragement and guidance. His support has helped turn my ambition to become an academic researcher into a reality. I would also like to thank Professor Martin Landray (Professor of Medicine and Epidemiology, Big Data Institute, University of Oxford and fellow alumni of University of Birmingham) for all his support and guidance with undertaking clinical trials. I am extremely grateful for the kindness, encouragement and support of my clinical supervisor, Dr Edward Sharples (Consultant Nephrologist, Oxford University Hospitals NHS Foundation Trust). He has provided great mentorship, advice and friendship throughout my nephrology training and my time out of programme for research. Dr Daniel Mitchell, Co-Supervisor, (University of Warwick) has been extremely helpful, patient and generous with his time and provided invaluable support and assistance with completion of my thesis. I am also hugely thankful to Dr Natalie Staplin, Senior Statistician (MRC PHRU, University of Oxford), for all her guidance, assistance, time and friendship. Without her input and support the analyses presented within this thesis, and the many co-authored publications, would not have been possible. 10 I appreciate the support, teaching and mentorship I received from Dr William Herrington (Senior Clinical Research Fellow, Renal Studies Group, University of Oxford) on clinical trials and epidemiology and, for providing me with the opportunities to collaborate with him on a range of observational analyses. I would like to thank all of
Load more

Recommended publications
  • Old Road Campus
    Old Road Campus 4a, 4b, 4c, U5 n o t Oxford City Centre g OLD ROAD n i d 4a, 4b, 4c, U5 a e H K O L L A D R O W AD E M I L 4,4a,4b,4c, U1X,U5 A41 42 4,4a,4b,4c,U5 Rin D 4 g R oad 6 7 1 13 3 11 C H U R C H I L L 900 D 2 R I 700, 900 V E E O x f o 5 A C rd 12 C i ty 10 C e n t re B 8 CAR PARK C 9 h u r c R F h i O l l O S H E o V s N E p L i T t DRI a VE ENTRANCE ROOSEVELT DRIVE l 900, ST2 Index 1 The Triangle Nursery 9 Old Road Campus Estates Annexe 13 Boundary Brook House Interserve Joint Research Office Kennedy Institute 2 - Research Services, Medical Sciences Division Old Road Campus Research Building 10 - Clinical Trials and Research Governance 3 New Richards Building Department of Oncology - Human Tissue Governance CRUK/MRC Oxford Institute for Radiation Oncology - Medical Sciences Division Business Development 4 NDM Research Building Institute of Biomedical Engineering Nuffield Department of Primary Care Health Sciences Target Discovery Institute Jenner Institute Medical Sciences Divisional Safety Officers Centre for Tropical Medicine and Global Health Bodleian Knowledge Centre (Library Services) Medical Sciences Division IT Services 5 Wellcome Centre for Human Genetics (WHG) Ludwig Institute for Cancer Research Structural Genomics Consortium 6 Henry Wellcome Building for Molecular Physiology Nuffield Department of Surgical Sciences Loading Bays and Delivery Offices of the Nuffield Professor of Medicine ENTRANCE VIA BUILDING 5 11 Big Data Institute A Wellcome Trust Centre for Human Genetics 7 Henry Wellcome Building for Particle Imaging
    [Show full text]
  • Richard Doll
    2825 Obituary: Richard Doll Sir Richard Doll died earlier this year at age 92. The most The studies by Doll are bold and original science. They celebrated epidemiologist of the 20th century, Doll is best represent an important part of the foundation of modern known for his work on smoking and lung cancer, but there was population-based chronic disease research. By the early 1960s, so much more to his career. they constituted adequate evidence for public health action to His father was a general practitioner in London, and it was reduce tobacco smoking; in 1964, the U.S. Surgeon General’s from St. Thomas’s that Doll himself graduated in Medicine in first report on the adverse health consequences of tobacco was 1937. Even as a student, he showed his interest in epidemi- published. Today, they continue to remind us how carefully ologic and statistical tools, publishing on the need for proper crafted observational studies can advance scientific knowledge analysis and statistical testing in population studies of disease. regarding social and health issues that are not amenable to Later, Doll served in the Royal Medical Corps in France and experimentation on human populations. the Middle East throughout the Second World War. He began Asbestos. By the early 1930s, work in the asbestos products his research career at the Middlesex Hospital, studying industry in Britain was known to increase the risk of a occupational factors in the development of peptic ulceration. sometimes fatal nonmalignant pulmonary disease, termed He married Dr. Joan Faulkner around this time, and it was she asbestosis.
    [Show full text]
  • Sir Richard Doll, Epidemiologist – a Personal Reminiscence with a Selected Bibliography
    British Journal of Cancer (2005) 93, 963 – 966 & 2005 Cancer Research UK All rights reserved 0007 – 0920/05 $30.00 www.bjcancer.com Obituary Sir Richard Doll, epidemiologist – a personal reminiscence with a selected bibliography The death of Richard Doll on 24 July 2005 at the age of 92 after a short illness ended an extraordinarily productive life in science for which he received widespread recognition, including Fellowship of The Royal Society (1966), Knighthood (1971), Companionship of Honour (1996), and many honorary degrees and prizes. He is unique, however, in having seen both universal acceptance of his work demonstrating smoking as the main cause of the most common fatal cancer in the world and the relative success of strategies to reduce the prevalence of the habit. In 1950, 80% of the men in Britain smoked but this has now declined to less than 30%. Richard Doll qualified in medicine at St Thomas’ Hospital in 1937, but his epidemiological career began after service in the Second World War when he worked with Francis Avery Jones at the Central Middlesex Hospital on occupational factors in the aetiology of peptic ulceration. The completeness of Doll’s tracing of previously surveyed men so impressed Tony Bradford Hill that he offered him a post in the MRC Statistical Research Unit to investigate the causes of lung cancer. For the representations of Percy Stocks (Chief Medical Officer to the Registrar General) and Sir Ernest Kennaway had prevailed against the then commonly held view that the marked rise in lung cancer deaths in Britain since 1900 was due only to improved diagnosis.
    [Show full text]
  • Understanding Genetics: DNA, Genes, and Their Real-World Applications Parts I & II Professor David Sadava
    Understanding Genetics: DNA, Genes, and Their Real-World Applications Parts I & II Professor David Sadava THE TEACHING COMPANY ® Table of Contents Understanding Genetics: DNA, Genes, and Their Real-World Applications Professor Biography..............................................................................................................................................iii Course Scope...........................................................................................................................................................1 Lecture One Our Inheritance...................................................................................................................................2 Lecture Two Mendel and Genes..............................................................................................................................4 Lecture Three Genes and Chromosomes................................................................................................................7 Lecture Four The Search for the Gene—DNA.......................................................................................................9 Lecture Five DNA Structure and Replication.......................................................................................................12 Lecture Six DNA Expression in Proteins..............................................................................................................14 Lecture Seven Genes, Enzymes, and Metabolism.................................................................................................17
    [Show full text]
  • Article the Effect of Lowering LDL Cholesterol on Vascular
    Article The Effect of Lowering LDL Cholesterol on Vascular Access Patency: Post Hoc Analysis of the Study of Heart and Renal Protection William Herrington, Jonathan Emberson, Natalie Staplin, Lisa Blackwell, Bengt Fellstro¨m, Robert Walker, Adeera Levin, Lai Seong Hooi, Ziad A. Massy, Vladimir Tesar, Christina Reith, Richard Haynes, Colin Baigent, and Martin J. Landray on behalf of the SHARP Investigators Due to the number of contributing authors, Abstract the affiliations are Background and objectives Reducing LDL cholesterol (LDL-C) with statin-based therapy reduces the risk of provided in the major atherosclerotic events among patients with CKD, including dialysis patients, but the effect of lowering Supplemental LDL-C on vascular access patency is unclear. Material. Design, setting, participants, & measurements The Study of Heart and Renal Protection (SHARP) randomized Correspondence: Dr. Martin J. Landray, patients with CKD to 20 mg simvastatin plus 10 mg ezetimibe daily versus matching placebo. This study aimed to Clinical Trial Service explore the effects of treatment on vascular access occlusive events, defined as any access revision procedure, Unit and access thrombosis, removal of an old dialysis access, or formation of new permanent dialysis access. Epidemiological Studies Unit, Nuffield Results Among 2353 SHARP participants who had functioning vascular access at randomization, allocation to Department of Population Health, simvastatin plus ezetimibe resulted in a 13% proportional reduction in vascular access occlusive events (355 Richard Doll Building, [29.7%] for simvastatin/ezetimibe versus 388 [33.5%] for placebo; risk ratio [RR], 0.87; 95% confidence interval Old Road Campus, [95% CI], 0.75 to 1.00; P=0.05).
    [Show full text]
  • The Impact of NMR and MRI
    WELLCOME WITNESSES TO TWENTIETH CENTURY MEDICINE _____________________________________________________________________________ MAKING THE HUMAN BODY TRANSPARENT: THE IMPACT OF NUCLEAR MAGNETIC RESONANCE AND MAGNETIC RESONANCE IMAGING _________________________________________________ RESEARCH IN GENERAL PRACTICE __________________________________ DRUGS IN PSYCHIATRIC PRACTICE ______________________ THE MRC COMMON COLD UNIT ____________________________________ WITNESS SEMINAR TRANSCRIPTS EDITED BY: E M TANSEY D A CHRISTIE L A REYNOLDS Volume Two – September 1998 ©The Trustee of the Wellcome Trust, London, 1998 First published by the Wellcome Trust, 1998 Occasional Publication no. 6, 1998 The Wellcome Trust is a registered charity, no. 210183. ISBN 978 186983 539 1 All volumes are freely available online at www.history.qmul.ac.uk/research/modbiomed/wellcome_witnesses/ Please cite as : Tansey E M, Christie D A, Reynolds L A. (eds) (1998) Wellcome Witnesses to Twentieth Century Medicine, vol. 2. London: Wellcome Trust. Key Front cover photographs, L to R from the top: Professor Sir Godfrey Hounsfield, speaking (NMR) Professor Robert Steiner, Professor Sir Martin Wood, Professor Sir Rex Richards (NMR) Dr Alan Broadhurst, Dr David Healy (Psy) Dr James Lovelock, Mrs Betty Porterfield (CCU) Professor Alec Jenner (Psy) Professor David Hannay (GPs) Dr Donna Chaproniere (CCU) Professor Merton Sandler (Psy) Professor George Radda (NMR) Mr Keith (Tom) Thompson (CCU) Back cover photographs, L to R, from the top: Professor Hannah Steinberg, Professor
    [Show full text]
  • 1 RECOVERY Central Coordinating Office Nuffield Department Of
    RECOVERY Central Coordinating Office Nuffield Department of Population Health Richard Doll Building Old Road Campus Roosevelt Drive Oxford OX3 7LF 24th May 2020 To all RECOVERY Principal Investigators Recruitment to the RECOVERY trial (including the Hydroxychloroquine arm) REMAINS OPEN On Friday 22nd May we received a letter from the MHRA in which they notified us of their concerns relating to the use of hydroxychloroquine as a treatment for patients with COVID-19 in the light of the recent publication by Mehra et al in The Lancet on 22 May 2020. We have held two videoconferences with the MHRA and provided a detailed response which is summarised below. This morning we have received written confirmation from the MHRA that, “it is acceptable to allow continued randomisation into the hydroxychloroquine arm of the trial.” Further details are provided below: • There have been two recent observational analyses of the use of hydroxychloroquine (HCQ) for treatment of COVID-19. One reported no significant effect on the outcome of intubation or death (Geleris et al, New Engl J Med 7 May 2020), while the other reported a hazard ratio of 1.33 for all-cause mortality (Mehra et al, Lancet 22 May 2020). The authors of both papers conclude that their findings should be interpreted with caution, are not definitive, and that randomised controlled trials are required to reach any conclusion about the benefit or harm of HCQ for COVID-19. • The RECOVERY trial is currently the largest randomised controlled trial of HCQ for COVID-19 but is not yet sufficiently large to detect (or rule out) moderate yet important treatment effects.
    [Show full text]
  • Nuffield Department of Population Health
    Nuffield Department of Population Health Richard Doll Building, Old Road Campus, Headington, Oxford OX3 7LF Tel: +44 (0)1865 743743, Fax: +44 (0)1865 743985, email: [email protected] _______________________________________________________________________________________________ 14 April 2014 Dr Fiona Godlee Editor, BMJ BMJ Publishing Group Tavistock Square London WC1H 9JR Dear Fiona NOT FOR PUBLICATION Thank you for responding so rapidly to my letter of 31 March, but unfortunately the key points that I raised have not been addressed properly either by the letters from Abramson et al and Malhotra or by your response of 1 April. I can assure you that this issue is not at all personal. As indicated previously, it seems highly likely that the misleading claims that have been reported by the BMJ about side- effect rates with statins will lead to large numbers of unnecessary heart attacks, strokes and premature deaths because patients at elevated risk will be dissuaded from taking statins. My concern is with the BMJ’s failure to correct promptly and prominently such a serious mistake when it has major public health implications. As I explained to you when we met, the evidence cited by Abramson et al and Malhotra does not support their claims that statins cause side-effects in 18-20% of patients. For the sake of clarity, a “statin-related adverse event” (which is what was studied in the paper by Zhang et al that is being cited) is not necessarily caused by, or a side-effect of, a statin. Consequently, it is a serious misrepresentation of the evidence for Abramson et al and Malhotra to state that it is.
    [Show full text]
  • Yale Medicine Magazine
    contents 2 Letters 4 Chronicle 10 Rounds 14 Findings 17 On Campus 18 Capsule 20 A dramatic turn The doctor-patient relationship takes center stage in performer Anna Deavere Smith’s interpretation of medicine at Yale. Yale Medicine Alumni Bulletin of the By Cathy Shufro Yale University School of Medicine Spring 2001 Volume 35, No. 2 28 Learning for the long run Editor-in-Chief Michael Kashgarian, M.D. Professor of Pathology and Biology For a quarter-century the Wednesday Evening Clinic Publisher has offered steady care to patients and an Jane E. Reynolds unequalled lesson in medicine to Yale students. Associate Dean By John Curtis Editor Michael Fitzsousa Director of Publications Associate Editor 34 “Adrenaline and the ordinary, John Curtis in varying proportions” Contributing Editors Sandra J. Ackerman Rachel Engers A student’s exposure to medicine in this former Soviet Sharon McManus republic reveals a different rhythm in the OR and a vastly Pem McNerny Karen Peart different take on relations between doctor and patient. Cathy Shufro Letter from Armenia by Sharon Anoush Chekijian Jacqueline Weaver Marc Wortman, Ph.D. Copy Editing Anne Sommer 42 Faculty News Office Manager / Editorial Assistant Claire M. Bessinger 46 Student News Senior Administrative Assistant Cheryl R. Violante 50 Alumni News Design Peter Johnson and Daphne Geismar 54 Archives Yale RIS Graphic Design Printing 55 In Memoriam W.E. Andrews of Connecticut Inc. Yale Medicine is distributed to alumni, faculty, students and friends of the School of Medicine, as well as leaders in Yale University alumni activities. Address correspondence to: Editor, Yale Medicine P.O.
    [Show full text]
  • Conclusions from a Kidney Disease-Improving Global Outcomes
    Challenges in conducting clinical trials in nephrology conclusions from a Kidney Disease—Improving Global Outcomes (KDIGO) Controversies Conference Baigent, Colin; Herrington, William G.; Coresh, Josef; Landray, Martin J.; Levin, Adeera; Perkovic, Vlado; Pfeffer, Marc A.; Rossing, Peter; Walsh, Michael; Wanner, Christoph; Wheeler, David C.; Winkelmayer, Wolfgang C.; McMurray, John J.V.; KDIGO Controversies Conference on Challenges in the Conduct of Clinical Trials in Nephrology Conference Participants; Abu-Alfa, Ali; Archdeacon, Patrick; Block, Geoffrey A.; Caskey, Fergus J.; Cheung, Alfred K.; Cooper, Bruce; Craig, Jonathan C.; Dember, Laura M.; Eknoyan, Garabed; Gansevoort, Ron T.; Gill, John S.; Gillespie, Barbara; Greene, Tom; Harris, David C.; Haynes, Richard; Hemmelgarn, Brenda R.; Herzog, Charles A.; Hiemstra, Thomas F.; Inker, Lesley A.; Jardine, Meg J.; Jha, Vivekanand; Jiang, Lixin; Johansen, Kirsten L.; Kewalramani, Reshma; Lambers Heerspink, Hiddo J.; Lefkowitz, Martin; Lok, Charmaine E.; Loud, Fiona; Maiulaitis, Romaldas; Maddux, Dugan W.; Maddux, Franklin W.; Madero, Magdalena; Mariz, Segundo; Mauer, Michael; Nally, Joseph V.; Nangaku, Masaomi; Okpechi, Ikechi G. Published in: Kidney International DOI: 10.1016/j.kint.2017.04.019 Publication date: 2017 Document version Publisher's PDF, also known as Version of record Document license: CC BY Citation for published version (APA): Baigent, C., Herrington, W. G., Coresh, J., Landray, M. J., Levin, A., Perkovic, V., Pfeffer, M. A., Rossing, P., Walsh, M., Wanner, C., Wheeler, D. C., Winkelmayer, W. C., McMurray, J. J. V., KDIGO Controversies Conference on Challenges in the Conduct of Clinical Trials in Nephrology Conference Participants, Abu-Alfa, A., Archdeacon, P., Block, G. A., Caskey, F. J., Cheung, A. K., ... Okpechi, I.
    [Show full text]
  • Bruce N. Ames
    Oral History Center University of California The Bancroft Library Berkeley, California Bruce N. Ames Bruce N. Ames: The Marriage of Biochemistry and Genetics at Caltech, the NIH, UC Berkeley, and CHORI, 1954–2018 University History Interviews conducted by Paul Burnett in 2019 and 2020 Copyright © 2021 by The Regents of the University of California Oral History Center, The Bancroft Library, University of California, Berkeley ii Since 1953 the Oral History Center of The Bancroft Library, formerly the Regional Oral History Office, has been interviewing leading participants in or well-placed witnesses to major events in the development of Northern California, the West, and the nation. Oral History is a method of collecting historical information through recorded interviews between a narrator with firsthand knowledge of historically significant events and a well-informed interviewer, with the goal of preserving substantive additions to the historical record. The recording is transcribed, lightly edited for continuity and clarity, and reviewed by the interviewee. The corrected manuscript is bound with photographs and illustrative materials and placed in The Bancroft Library at the University of California, Berkeley, and in other research collections for scholarly use. Because it is primary material, oral history is not intended to present the final, verified, or complete narrative of events. It is a spoken account, offered by the interviewee in response to questioning, and as such it is reflective, partisan, deeply involved, and irreplaceable. ********************************* All uses of this manuscript are covered by a legal agreement between The Regents of the University of California and Bruce N. Ames dated January 20, 2021. The manuscript is thereby made available for research purposes.
    [Show full text]
  • The Shaw Prize Founder's Biographical Note
    The Shaw Prize The Shaw Prize is an international award to honour individuals who are currently active in their respective fields and who have achieved distinguished and significant advances, who have made outstanding contributions in culture and the arts, or who in other domains have achieved excellence. The award is dedicated to furthering societal progress, enhancing quality of life, and enriching humanity's spiritual civilization. Preference will be given to individuals whose significant work was recently achieved. Founder's Biographical Note The Shaw Prize was established under the auspices of Mr. Run Run Shaw. Mr. Shaw, born in China in 1907, is a native of Ningbo County, Zhejiang Province. He joined his brother's film company in China in the 1920s. In the 1950s he founded the film company Shaw Brothers (Hong Kong) Limited in Hong Kong. He has been Executive Chairman of Television Broadcasts Limited in Hong Kong since the 1970s. Mr. Shaw has also founded two charities, The Sir Run Run Shaw Charitable Trust and The Shaw Foundation Hong Kong, both dedicated to the promotion of education, scientific and technological research, medical and welfare services, and culture and the arts. ~ 1 ~ Message from the Chief Executive Message from the Founder This year's Shaw Prize is proof that Education holds the key to the power of science is as strong as progress and has long been ever in the 21st Century. It continues to push back the recognized and revered as the boundaries of science for the good of all mankind. foundation upon which future I am pleased to congratulate the success will be achieved.
    [Show full text]